PARTIKULA

Partikula utilizes its proprietary chemical engineering technologies to develop compounds that specifically and directly target mitochondria, from the outer mitochondrial membrane to the mitochondrial matrix and areas in between. By utilizing their technologies they can now access a large number of important and in some cases well-studies targets that until now have been difficult to target with traditional therapies. Their initial clinical focus is in oncology although they do have programs in earlier stages of development in the areas of neurodegenerative, cardiovascular, and orphan mitochondrial disease.